5AM Ventures - Company Portfolio

	Achaogen, an infectious disease therapeutics company founded out of The Scripps Research Institute, develops solutions to the problem of drug resistance.
	Alexza, a drug delivery company founded by Dr. Alejandro Zaffaroni, utilizes a novel technology that leverages the pharmacodynamics of existing therapies to rapidly deliver drugs locally and systemically through the lung. Went public in March 2006.
	Ambrx, a protein therapeutics company, exploits technology developed by Prof. Peter Schultz in the novel field of protein medicinal chemistry that enables the development of proteins with new and improved physical, chemical, and pharmacological properties.
	Ceterix Orthopedics, a sports medicine medical device company, develops technologies to address unmet clinical needs in arthroscopic surgery.
	Cleave Biosciences, an oncology therapeutics company founded by leading drug developers and academics, develops targeted therapies for specific patient populations by modulating protein homeostasis, an important emerging target in cancer.
	DVS Sciences, an analytical instrument and reagents company founded in Toronto, Canada produces and markets the CyTOF® Mass Cytometer, a next-generation highly multiplexed single cell analyzer which enables new scientific insights into complex biological cellular networks.
	Envoy, a platform CNS drug discovery company spun out of decades of work at the Rockefeller University, uses bacTRAP© technology to conduct detailed analysis of gene translational profiles in individual cell types in complex, multi-cellular organs. Acquired by Takeda in November 2012.
	Epirus, a biopharmaceutical company, focused on becoming leader in biosimilars for the emerging markets.
	With a focus on inflammatory diseases, Flexion is developing novel therapeutics for the targeted treatment of musculoskeletal disorders.
	Igenica, a monoclonal-antibody discovery and development company, leverages innovative platform screening technologies to identify novel therapeutics for cancer.
	Ikaria, a fully-integrated biotherapeutics company focused on developing and commercializing innovative therapeutics designed to meet the significant unmet medical needs of critically ill patients.
	Ilypsa, a spinout of Symyx Technologies (NASDAQ: SMMX), leveraged Symyx's existing high-throughput technologies to discover and develop new polymer-based therapeutics. Acquired by Amgen in July 2007.
	Incline, a hospital-focused specialty pharmaceutical company focused on the development of IONSYS (fentanyl iontophoretic transdermal system), a novel pain product intended to provide patient-controlled analgesia for patients following surgery.
	KaloBios, a monoclonal antibody company, develops first- or best-in-class antibody therapeutics in the fields of autoimmunity, anti-infectives and oncology.
	Kinestral, is developing novel new technologies applied to building materials for energy efficiency.
	Marcadia, a peptide therapeutics company, leverages the work of Prof. Richard DiMarchi to develop a portfolio of novel therapeutics for metabolic diseases. Acquired by Roche in December 2010.
	Miikana, a clinically-driven oncology company founded out of the former Amgen Institute, develops small molecule therapeutics for cancer. Acquired by EntreMed in January 2006.
	Novira, an antivirals company developing first-in-class treatments addressing viral infections with major unmet needs.
	Panomics (formerly Genospectra), a life science reagents company, develops novel cell-based assays and tools to enable multiplexed measurements of molecular events in a quantitative and scalable manner. Acquired by Affymetrix in December 2008.
	Pearl, a spinout of Nektar (NASDAQ: NKTR), develops products for the treatment and prevention of inflammatory, obstructive and allergic conditions in respiratory diseases.
	PhaseRx, a biopharmaceutical company, develops novel approaches to the delivery of siRNA and other macromolecules. The core delivery platform is based on polymer technology developed at the University of Washington.
	Pulmatrix, is discovering a new class of host-targeted therapies that pathogen independently treat, prevent and help control a broad range of respiratory infections and progressive respiratory diseases offering potential for individual therapies that treat serious diseases including influenza, rhinovirus, COPD, asthma and cystic fibrosis.
	Relypsa, a biopharmaceutical company spun out following the acquisition of Ilypsa by Amgen, leads the discovery and development of new non-absorbed polymeric drugs.
	Rennovia, an early stage chemical company, is developing processes to make high-value known chemicals derived from renewable bio sources that have both financial and green advantages.
	RuiYi (formerly Anaphore), a drug discovery and development company focused on first-in-class antibodies targeting G protein coupled receptors (GPCRs)..
	Semprus Biosciences, a biomedical company, develops long-lasting anti-microbial and anti-thrombotic surface technologies that are incorporated into medical devices. Teleflex Incorporated (NYSE: TFX), a leading global provider of medical devices for critical care and surgery, acquired Semprus in May 2012.
	Synosia, a drug development company, develops innovative treatments for disorders of the central nervous system. Acquired by Biotie Therapies in February 2011.
	VBI Vaccines, is a vaccine development company dedicated to the innovative formulation, development and delivery of thermostable vaccines and VLP antigens.
	Viveve, is a medical device company devoted to enhancing a woman's sexual health post-childbirth. The Company has developed a non-surgical, 30-minute procedure performed in an OB/GYN office to increase vaginal tightness.
	WaveRx, a medical device company, develops novel technologies for dermatological disorders of the nail.
	Wildcat Discovery, a materials science company, pioneers novel high-throughput discovery and assay methods to accelerate the development of advanced materials for energy storage applications including Lithium ion batteries.